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Autoimmune disorders constitute a diverse group of phenotypes with overlapping features and a tendency toward
familial aggregation. It is likely that common underlying genes are involved in these disorders. Until very recently,
no specific alleles—aside from a few common human leukocyte antigen class II genes—had been identified that
clearly associate with multiple different autoimmune diseases. In this study, we describe a unique collection of 265
multiplex families assembled by the Multiple Autoimmune Disease Genetics Consortium (MADGC). At least two
of nine “core” autoimmune diseases are present in each of these families. These core diseases include rheumatoid
arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), multiple sclerosis (MS), autoimmune
thyroid disease (Hashimoto thyroiditis or Graves disease), juvenile RA, inflammatory bowel disease (Crohn disease
or ulcerative colitis), psoriasis, and primary Sjo¨gren syndrome. We report that a recently described functional single-
nucleotide polymorphism (rs2476601, encoding R620W) in the intracellular tyrosine phosphatase (PTPN22) confers
risk of four separate autoimmune phenotypes in these families: T1D, RA, SLE, and Hashimoto thyroiditis. MS did
not show association with the PTPN22 risk allele. These findings suggest a common underlying etiologic pathway
for some, but not all, autoimmune disorders, and they suggest that MS may have a pathogenesis that is distinct
from RA, SLE, and T1D. DNA and clinical data for the MADGC families are available to the scientific community;
these data will provide a valuable resource for the dissection of the complex genetic factors that underlie the various
autoimmune phenotypes.
Introduction
Autoimmune diseases share a number of characteristics
that suggest common etiologic pathways or mechanisms,
including reactivity to self-antigens by the humoral and/
or cellular immune system, as well as genetic associations
with human leukocyte antigen (HLA). Although familial
clustering of autoimmunity has long been recognized, the
patterns of aggregation across different autoimmune dis-
eases have not been clearly delineated. Certain rare fa-
milial clusters of autoimmune phenotypes, such as the
polyglandular autoimmune endocrinopathies, are known
to have a common genetic basis (Eisenbarth and Gott-
lieb 2004). Among the more common autoimmune dis-
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orders, probably the best evidence for familial clustering
among different autoimmune diseases involves rheuma-
toid arthritis (RA [MIM 180300]), autoimmune thyroid
disease (AITD) (especially Hashimoto thyroiditis [MIM
140300]), and type 1 diabetes (T1D [MIM 222100])
(Torfs et al. 1986; Lin et al. 1998). However, the degree
and significance of familial clustering among the larger
group of autoimmune disorders is uncertain; only a few
large or well-controlled epidemiological studies of this
issue have been reported (Torfs et al. 1986; Ginn et al.
1998; Lin et al. 1998; Broadley et al. 2000), in part, be-
cause many of these diseases are relatively uncommon and
have heterogeneous phenotypes that are difficult to con-
firm in population surveys.
Clustering of diseases within families may be explained
by shared environmental exposures, shared genes, or in-
teractions between genetic and environmental factors. A
growing body of evidence suggests that exposure to cig-
arette smoke, for example, may increase the risk of mul-
tiple autoimmune diseases, including AITD (Vestergaard
2002), RA (Heliovaara et al. 1993; Symmons et al. 1997;
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Table 1
Demographic Characteristics of 265 Multiplex Autoimmune
Families
Characteristic Finding
Mean no. of affected individuals per family (range) 3.2 (2–9)
Mean total no. of individualsa enrolled per family
(range)
5.7 (2–19)
Ethnicityb (% white) 96.6
No. from recruitment source (%):
Patient advocacy group/publication 128 (48)
Other 80 (30)
Local recruitmentc 57 (22)
a Affected plus unaffected.
b Other ethnicities included Hispanic (1.1%), mixed ethnicity
(1.9%), and unknown ethnicity (0.4%).
c Enrollment at these sites included recruitment onsite (e.g., clinics)
and offsite (e.g., patients known to investigators through other re-
search activities).
Uhlig et al. 1999), systemic lupus erythematosus (SLE
[MIM 152700]) (Hardy et al. 1998; Bengtsson et al.
2002), and multiple sclerosis (MS [MIM 126200]) (Riise
et al. 2003). Exposure to crystalline silica (Steenland and
Goldsmith 1995) and to Epstein-Barr virus infection
(Harley and James 1999; James et al. 2001) also appears
to influence the risk of multiple autoimmune diseases. In
addition to these environmental factors, there is now in-
creasing evidence that common genes may underlie au-
toimmunity. Becker and colleagues (1998) have described
a pooled analysis of genome-screening results and have
identified 18 distinct clusters with evidence of genetic
linkage to two or more autoimmune or immune dis-
orders. However, evidence that specific risk alleles are
associated with multiple autoimmune diseases is rela-
tively sparse. Even within the HLA system, different al-
leles are associated with different autoimmune pheno-
types (Todd et al. 1988; Hall et al. 1996; Tan and Arnett
1998; Barcellos et al. 2003), and, indeed, it is not always
clear that the HLA alleles are the only relevant risk factor
within the major histocompatibility complex (MHC) (Ja-
waheer et al. 2002). Until very recently, CTLA4 was the
only gene that had been convincingly associated with two
different autoimmune diseases—AITD and T1D—but
the strength of these associations is rather modest, with
odds ratios (ORs) of ∼1.45 and ∼1.15, respectively (Ueda
et al. 2003).
In this study, we describe a unique registry of 265
multiplex families that have been specifically identified
as having two or more different autoimmune diseases in
the same family. Detailed clinical data for each family
member—along with a blood sample—have been col-
lected by the Multiple Autoimmune Disease Genetics
Consortium (MADGC), under a contract with the Na-
tional Institute of Allergy and Infectious Diseases
(NIAID). Genetic analysis of these families reveals that
PTPN22 is associated with several different autoimmune
disorders, confirming and extending several recent re-
ports (Begovich et al. 2004; Bottini et al. 2004; Kyogoku
et al. 2004). For the first time, we demonstrate an asso-
ciation with Hashimoto thyroiditis, a common form of
AITD. This work establishes PTPN22 as the first major
genetic variant that clearly confers substantial risk of
multiple different autoimmune phenotypes, and it points
the way to understanding common disease mechanisms.
The MADGC collection of multiplex families is likely to
provide an important scientific resource for further stud-
ies in this area.
Material and Methods
Multiplex Families: Entry Criteria and Approach
to Recruitment
At the request of NIAID, investigators with expertise
in the genetics of a wide range of autoimmune diseases
were asked to serve as consultants for this effort and met
with the study investigators at the National Institutes
of Health on November 1, 1999 (see the “Acknowledg-
ments” section for the names of participants). The pri-
mary goal of that meeting was to determine which au-
toimmune diseases should be included in the collection,
on the basis of a variety of considerations, including
strength of evidence for genetic susceptibility, clustering
with other autoimmune diseases, population prevalence,
impact on public health, and feasibility of collection. Eight
“core” autoimmune diseases were targeted initially: adult
RA, SLE, MS, AITD (Graves disease [MIM 275000] or
Hashimoto thyroiditis), T1D, psoriasis (MIM 177900),
inflammatory bowel disease (IBD [MIM 266600]) (Crohn
disease or ulcerative colitis), and juvenile rheumatoid ar-
thritis (JRA [MIM 604302]). Subsequently, primary Sjo¨-
gren syndrome (SS [MIM 270150]) was added to this
core list of diseases. To be eligible for inclusion in the
registry/repository, the multiplex families were required
to have at least two members affected with at least two
of these nine core diseases. Furthermore, at least two of
the affected members had to be informative for linkage
(e.g., a single affected parent/offspring pair would not
meet enrollment criteria).
Families were recruited from a variety of sources, in-
cluding patient advocacy groups and publications (e.g.,
the American Autoimmune Related Diseases Association
[AARDA] and the Multiple Sclerosis Quarterly Report),
as well as other forms of publicity and direct mailing of
flyers and posters to physicians’ offices. Once a family
was deemed eligible for inclusion, all individuals affect-
ed with any autoimmune disease (see the MADGC Web
site) were invited to participate, as were all unaffected
individuals who were likely to be useful for genetic link-
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age or association studies. Informed consent was ob-
tained from all enrolled subjects, and the study was ap-
proved by the institutional review boards at each of the
three participating centers: North Shore University Hos-
pital, University of Minnesota, and University of Cali-
fornia San Francisco (UCSF).
Demographic and Clinical Information
Basic demographic information was collected from all
enrolled subjects via telephone or mailed questionnaire.
All subjects were also asked about the presence of any
of the nine core diseases or other autoimmune diseases.
Subjects who reported at least one of these conditions
provided additional clinical information over the tele-
phone, including date of diagnosis; name, address, and
specialty of treating physician(s); and a history of the
symptoms and treatment received for the disease(s). Spe-
cific lists of symptoms and treatments were developed
for each of the nine core diseases with the assistance of
the aforementioned consultants; these lists are available
either by request from the authors or on the MADGC
Web site. For other autoimmune diseases (i.e., noncore
diseases), similar information was collected using a stan-
dardized form that was designed to be more general.
Confirmation of Autoimmune Disease Diagnoses
Autoimmune disease diagnoses were confirmed either
by the treating physician or on the basis of a review of
medical records by one of the study investigators or con-
sultants. Criteria for diagnostic confirmation were those
established either by the appropriate professional body
(e.g., American College of Rheumatology) or on the ad-
vice of consultants. Standardized diagnostic confirmation
forms were developed for each of the nine core diseases
and were completed by the confirming physician/inves-
tigator. For use in documenting diagnosis of other auto-
immune diseases, a more general form was developed for
completion by the study physician/investigator. All sub-
jects who reported an autoimmune disease that could not
be confirmed were considered “unknown” for that dis-
ease, unless it was clear from the available information
that the disease was not present. Subjects could be con-
firmed for more than one autoimmune disease, or they
could be confirmed for one or more diseases and consid-
ered unknown for other autoimmune diseases.
Collection of Biological Material
All enrollees were asked to provide blood for pro-
cessing and storage at a centralized biorepository located
at the North Shore Long Island Jewish Research Insti-
tute. Samples were processed and were stored as plasma
and as frozen viable peripheral blood mononuclear cells
(PBMCs). After shipment of frozen PBMCs in batches,
immortalized lymphoblastoid cell lines were successfully
established from the majority of samples at a second site
(University of Minnesota). As a security precaution, all
samples are stored in at least two geographically separate
sites (Manhasset and Minneapolis).
White control subjects ( ) were derived fromnp 2,064
several sample sets. The PTPN22 genotyping data for the
majority of these control subjects have all been report-
ed elsewhere (Begovich et al. 2004; Kyogoku et al. 2004).
Additional PTPN22 typing for this study was performed
on 103 white subjects derived from the New York Cancer
Project collection (Mitchell et al. 2004).
Genotyping
To confirm family relationships, all samples were ge-
notyped, as described elsewhere (Baechler et al. 2003),
for a set of ∼100 polymorphic markers (ABI, version
2.5; marker sets 1–7) and were analyzed using the pro-
grams Relative (Go¨ring and Ott 1997) and PedCheck
(O’Connell and Weeks 1998). HLA-DR typing was per-
formed at Roche Molecular Systems, as described else-
where (Erlich et al. 1991). Genotyping of the PTPN22
SNP (rs2476601, 1858CrT, R620W) was performed
using a PSQ HS 96A Pyrosequencer. A quantity of 2 ng
of DNA was amplified by PCR in a 10-ml reaction by
use of the following primers: 5′-GTTGCGCAGGCTAG-
TCTTGA-3′ (forward), 5′-GCTGCTCCGGTTCATAG-
ATTGGATAGCAACTGCTCCAAGG-3′ (reverse), and
5′-Biotin-GCTGCTCCGGTTCATAGATT-3′ (Univ1_B).
The addition of specific sequences to the 5′ end of the
reverse primer (shown in bold italics) allowed the use
of a biotinylated universal primer, Univ1_B. These prim-
ers were used at a ratio of 1:9 (reverse primer:universal
primer). PCR conditions were as follows: 95C for 12
min; 50 cycles at 95C for 45 s, at 56.4C for 45 s, and
at 72C for 45 s; and 72C for 10 min. The amplicon
was denatured with NaOH, separated, washed, and neu-
tralized. To detect the polymorphism, the sequencing
primer 5′-AAATGATTCAGGTGTCC-3′ was used in
combination with appropriate Pyrosequencing sub-
strates and enzymes, in accordance with manufacturer
instructions. Genotyping of PTPN22 R620W on control
subjects was performed as described elsewhere (Begovich
et al. 2004).
Data Management and Statistical Analysis
All demographic and clinical information was entered
into a Microsoft Access database. Pedigrees were created
for each family by use of the program Cyrillic, version
2.1 (Cherwell Scientific), and the pedigree data were im-
ported into the Access database. These core data are also
available upon request as downloadable Microsoft Excel
files (see the MADGC Web site). Information about bi-
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Figure 1 Distribution of the core autoimmune diseases among 806 affected members of 265 multiplex autoimmune families. Probands
are shown in the lower (unblackened) portion of bars; other affected individuals are shown in the upper (blackened) portion of bars. A total
of 907 instances of these core autoimmune diseases are tabulated, since 97 individuals had two or more such diseases (most frequently involving
AITD [see text]). IDDM p insulin-dependent diabetes mellitus.
ological material—such as sample status, sample loca-
tion, and genotyping results—is managed with a custom-
designed relational database in SQL at the North Shore
Long Island Jewish Research Institute.
Basic summary statistics were generated using the pro-
gram SAS, version 8.02 (SAS Institute). ORs and 95%
CIs were computed to describe associations between spe-
cific autoimmune diseases (and groups of autoimmune
diseases) and the presence of the minor allele of PTPN22,
on the basis of a comparison with control subjects. All
of the affected individuals in MADGC families were used
in these case-control association analyses. Since affected
siblings obtained from the same parental mating type ex-
hibit the same genotype and allele frequencies (W.L. and
P.K.G., unpublished results), the inclusion of more than
one affected sibling per family will not bias the estimates
of ORs, as long as no particular parental mating type is
over- or underrepresented in the sample. The inclusion of
affected relatives other than siblings has an even smaller
effect on an association analysis, because the genotype
correlation among distant relatives is much lower.
Results
Demographic and Disease Characteristics
of the MADGC Family Collection
The demographic and disease characteristics of the
MADGC family collection reflect, in part, the recommen-
dations of an expert advisory panel that was convened in
late 1999 (see the “Material and Methods” section). The
entry criteria for these families include a requirement for
at least two affected individuals per family and at least
two of the nine core diseases in these affected individuals.
Demographic characteristics of the currently enrolled
265 families with multiplex autoimmune diseases are
summarized in table 1. The majority of families were
white, with only nine families from other ethnic back-
grounds. Families consisted of an average of 3.2 affected
individuals, but 11 families each had between 6 and 9
affected individuals. Nearly half of the families (48%)
were recruited through patient advocacy groups, primar-
ily the AARDA and the National Multiple Sclerosis So-
ciety. Approximately 20% of the families were ascertained
by one of the three major recruitment sites for the
MADGC: North Shore University Hospital, the Univer-
sity of Minnesota, and UCSF. Since the emphasis of re-
search at these sites has been primarily on population-
genetics studies of SLE and/or RA, there is a relative
enrichment of probands with these rheumatic diseases.
The remaining families were recruited using a variety of
other approaches, including articles in the lay press. Thus,
by virtue of the criteria for entry and the modes of re-
cruitment, these families are not—and were not intended
to be—a representative sample of families with multiple
autoimmune diseases in the general population.
The distribution of the nine core diseases among all
806 affected individuals, as well as among the 265 pro-
bands in these families, is shown in figure 1. Note that
the total number of core diseases tallied in figure 1 (907)
exceeds the number of affected individuals (806) because
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Table 2
Comparison of Frequency of Autoimmune Diseases in Siblings in Family Groups, Stratified by Diagnosis
of Proband
FAMILY GROUPa
(NO. OF PROBANDS)
NO. OF
AFFECTED
SIBLINGS
NO. (%) OF SIBLINGS AFFECTED WITH
AITD RA MS SLE T1D IBD Psoriasis
All probands (265) 232 69 (30) 36 (16) 16 (7) 19 (8) 23 (10) 15 (6) 25 (11)
Probands with:
AITD (43) 40 19 (48)b 9 (23) 2 (5) 3 (8) 6 (15) 3 (8) 0 (0)
RA (46) 51 15 (29) 20 (39)c 2 (4) 2 (4) 3 (6) 5 (10) 6 (12)
MS (82) 64 17 (27) 5 (8) 3 (5) 6 (9) 9 (14) 7 (11) 12 (19)d
SLE (65) 53 23 (43)b 9 (17) 4 (8) 6 (11) 4 (8) 1 (2) 4 (8)
T1D (10) 9 2 (22) 0 (0) 0 (0) 1 (11) 3 (33)e 0 (0) 1 (11)
IBD (7) 8 2 (25) 1 (13) 3 (38)f 0 (0) 2 (25) 0 (0) 0 (0)
Psoriasis (8) 8 1 (13) 2 (25) 1 (13) 0 (0) 0 (0) 0 (0) 3 (38)
NOTE.—Bold italics indicate (two-sided Fisher’s exact test).P ! .1
a Stratified by proband diagnosis.
b AITD in siblings of probands with AITD: OR 2.13, 95% CI 1.08–4.2, ; AITD in siblings of probandsPp .043
with SLE: OR 1.81, 95% CI 0.98–3.34, .Pp .073
c RA in siblings of probands with RA: OR 3.5, 95% CI 1.8–6.8, .Pp .0003
d Psoriasis in siblings of probands with MS: OR 1.9, 95% CI 0.90–4.0, ; psoriasis in siblings of probandsPp .09
with psoriasis: OR 4.96, 95% CI 11.1–22.0, .Pp .053
e T1D in siblings of probands with T1D: OR 4.54, 95% CI 1.06–19.40, .Pp .06
f MS in siblings of probands with IBD: OR 8.1, 95% CI 1.77–37.0, .Pp .018
97 subjects were affected with two or more different
core diseases. Overall, AITD is the most common dis-
order among all affected family members. This is ex-
pected, given that it is the disorder with the highest pop-
ulation prevalence of the nine core diseases. MS, RA,
and SLE were the next most common diseases present
in these families. The high prevalence of RA in the fam-
ilies is not unexpected, given the overall ∼1% estimated
prevalence of this disease in the general population (Ga-
briel 2000). However, both SLE and MS are substan-
tially overrepresented—both among all affected individ-
uals and among the probands—compared with their low
population prevalence (Broadley et al. 2000; Gabriel
2000). This undoubtedly reflects the ascertainment bias
inherent in the modes of recruitment discussed above—
namely, that existing collections of patients with RA,
SLE, and MS were used as a source of recruitment for
∼20% of the MADGC families.
Despite the ascertainment bias in this collection, we
also examined the patterns of disease aggregation in the
MADGC families. In an attempt to reduce the effects of
ascertainment bias—as well as for simplicity of inter-
pretation and data presentation—we stratified the fam-
ilies by the seven most common diseases present in the
probands, and then we examined the distribution of
these seven diseases in the siblings of these probands.
We also calculated ORs to determine whether there was
any significant enrichment of particular autoimmune dis-
eases among siblings in families selected by proband di-
agnosis, compared with the distribution of these diseases
among all the affected siblings in the entire set of 265
families. The results are shown in table 2. For example,
the data show that AITD is present in 69 (30%) of the
232 siblings in the 265 families (first row). Among the
families in whom the proband has AITD, 19 (48%) of
the 40 siblings also have AITD (second row). This rep-
resents a nominally significant enrichment of AITD in
these siblings, compared with siblings overall in these
families (OR 2.13; 95% CI 1.08–4.2; [P valuePp .043
uncorrected]).
Similar trends toward disease aggregation among sib-
lings can be seen in table 2. However, with the exception
of families with multiple siblings with RA, none of these
associations remains significant after correcting for mul-
tiple comparisons. The reason for the enrichment of sib-
ling pairs with RA in these families is that a significant
number of these families were originally recruited from
pre-existing collections of sibling pairs with RA (Jawa-
heer et al. 2004). Therefore, although this collection of-
fers a rich resource of families with multiple autoimmune
diseases, it does not provide anything more than sug-
gestive information concerning the normal patterns of
familial aggregation of autoimmune diseases in the gen-
eral population.
High Degree of Female Predominance in RA and MS
As expected for autoimmune diseases in general, there
was a predominance of females among the affected mem-
bers of these families. Overall, 82% of affected individuals
were female, compared with 54% of unaffected individ-
uals who were contacted directly for the study. When all
unaffected individuals in the family are considered, re-
gardless of direct contact, 43% are female. This suggests
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Table 3
Sex Distribution among 806 Affected Members of 265 Multiplex
Autoimmune Families, by Core Autoimmune Disease
DISEASE (NO.
OF AFFECTED
SUBJECTSa)
% FEMALE
All Affected Individuals Probands Only
AITD (282) 88 100
MS (138) 85 93
RA (137) 89 93
SLE (113) 94 94
T1D (67) 57 100
Psoriasis (63) 68 100
IBD (61) 66 86
JRA (30) 83 100
SS (16) 94 100
a The total number of individuals exceeds 806 because of the pres-
ence of more than one autoimmune disease in some individuals.
Table 4
HLA-DR Associations with Selected Autoimmune Diseases
among 256 White Multiplex Autoimmune Families
DISEASE (NO.
OF INDIVIDUALS)
AND DR ALLELE
DR-ALLELE FREQUENCY
(%a) IN
OR (95% CI)bCases Controls
RA (129):
DR4 58 28 2.02 (1.62–2.42)
SLE (107):
DR2 35 29 1.2 (.91–1.59)
DR3 45 20 2.24 (1.75–2.87)
MS (135):
DR2 53 29 1.84 (1.54–2.24)
AITD (270):
DR3 38 20 1.89 (1.58–2.30)
T1D (65):
DR3 57 20 2.89 (2.24–3.65)
DR4 69 28 2.44 (2.0–2.96)
NOTE.—DR typing results are shown by use of serologic equiva-
lence. DR2 contains both DRB1*15 and DRB1*16 alleles, and DR4
contains all DRB1*04 subtypes.
a Frequency (%) is rounded to the nearest integer.
b Compared with a group of 926 white controls from the New York
metropolitan area.
an overall increase in females among participants versus
nonparticipants in the study. Nevertheless, the percentage
of females varied by autoimmune disease, ranging from
57% of individuals with T1D to 94% of individuals with
SLE and individuals with SS (see table 3). The degree of
enrichment for females was unexpectedly high for diseases
such as RA and MS, which typically exhibit 3:1 and 2:
1 female-to-male ratios, respectively, in sporadic cases.
The enrichment of females among all diseases is even more
dramatic if only probands are considered (table 3). This
may reflect a tendency for female subjects to be more
knowledgeable about family history and therefore more
likely to participate in family research studies. However,
it is possible that the female predominance in our families
may also have biological explanations, perhaps reflecting
enhanced penetrance in females when multiple risk genes
are present, as may be the case in these families.
HLA Typing Reveals Typical Patterns of Disease
Association
First-level DNA-based HLA-DR typing was performed
for all members of these multiplex families. Table 4 sum-
marizes the results for the five core diseases that have
widely recognized HLA-DR associations in whites—
namely, DR4 for RA, DR2 and DR3 for SLE, DR3 for
AITD, DR2 for MS, and DR3 and DR4 for T1D. The
frequencies of these HLA-DR allelic groups in a white
control population ( ) from the New York Cancernp 926
Project cohort are shown for comparison, with calculated
ORs. The observed HLA associations are consistent with
previous observations in white subjects with these dis-
orders (Hall et al. 1996; Tan and Arnett 1998; Todd et
al. 1988; Barcellos et al. 2003). Of course, recent studies
have indicated that additional loci, other than HLA-
DRB1, within the MHC also contribute to risk of several
autoimmune diseases (Graham et al. 2002; Jawaheer et
al. 2002; Harbo et al. 2004; Vandiedonck et al. 2004).
Other Autoimmune Diseases
One or more other (noncore) autoimmune diseases
were confirmed among 80 individuals (67 families). The
most frequent of these diseases were pernicious or he-
molytic anemia (MIM 170900 and MIM 205700, re-
spectively) (confirmed in 19 members of 14 families),
idiopathic thrombocytopenic purpura (MIM 188030)
(12 individuals), antiphospholipid syndrome (MIM
107320) (7 individuals), mixed or undifferentiated con-
nective tissue disease (6 individuals), scleroderma (MIM
181750) (6 individuals), and vitiligo (MIM 193200) (7
individuals).
Patterns of Disease Aggregation in Single Individuals
In the families we studied, 128 affected individuals
had more than one autoimmune disease. This includes
the 97 individuals with two or more core diseases, as
summarized in figure 1. The co-occurrence of AITD with
another disease was by far the most common pattern
and was present in 84 (65.6%) of the 128 subjects. These
included 13 subjects with MS/AITD, 23 subjects with
RA/AITD, 12 subjects with T1D/AITD, and 16 subjects
with SLE/AITD.
Association of the PTPN22 R620W Polymorphism
with Multiple Autoimmune Diseases
To begin to use this family resource to study gene-
tic polymorphisms that may underlie multiple autoim-
mune diseases, we genotyped 249 white families in this
initial collection for a case-control study of the PTPN22
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Table 5
Association of the PTPN22 Missense SNP with Four Autoimmune Diseases
in the White MADGC Families (249 Families, 746 Affected Individuals)
Autoimmune
Disease(s) No. of Cases
T-Allele
Frequency (%) OR (95% CI)a
T1D 61 18.9 2.49 (1.56–3.97)
Hashimoto thyroiditis 194 14.2 1.77 (1.31–2.40)
SLEb 101 12.9 1.58 (1.04–2.43)
RAc 122 11.9 1.45 (.97–2.16)
Graves disease 58 10.3 1.24 (.67–2.27)
MS 120 8.3 .98 (.61–1.56)
Psoriasis 51 7.8 .91 (.44–1.89)
JRA 27 7.4 .86 (.31–2.39)
IBD 41 7.3 .85 (.37–1.96)
SS 16 3.1 .35 (.05–2.54)
T1D, AITD, SLE, and RA 483 12.9 1.59 (1.28–1.98)
a The OR was calculated on the basis of a T-allele frequency of 8.5% in 2,064
white control subjects; 95% CIs are not corrected for the complex patterns of
relatedness of cases.
b Thirty-two cases from affected sib pair families reported elsewhere (Kyogoku
et al. 2004).
c Forty-three cases from affected sib pair families reported elsewhere (Begovich
et al. 2004).
R620W polymorphism. Recent studies have indicated
that PTPN22 is associated with T1D, RA, SLE, Graves
disease, and autoimmune Addison disease. No informa-
tion is currently available for other autoimmune disor-
ders, although unpublished data indicate that there is no
evidence of association with MS (Begovich et al. 2005).
Using a Pyrosequencing assay, we determined the prev-
alence of the minor (T) allele (rs2476601, encoding tryp-
tophan at amino acid position 620 of the full-length pro-
tein) in 746 affected members of these families, compared
with 2,064 healthy white controls (the majority of whom
had been genotyped previously) (Begovich et al. 2004;
Kyogoku et al. 2004).
The results, given in table 5, show striking variation
in genetic association for different diseases, with ORs
ranging from 0.35 to 2.49. When all 746 affected in-
dividuals were compared with controls, the combined
OR was 1.35 ( ). Notably, in addition to T1DPp .002
and SLE, Hashimoto thyroiditis was also significantly
associated with the 620W risk allele (OR 1.63; 95% CI
1.24–2.17). The association with RA was positive but
was of borderline significance. The OR for Graves dis-
ease was 11 but was not statistically significant. When
all individuals in disease groups with an OR of 11 (T1D,
SLE, AITD, and RA) were combined ( ), the cu-np 483
mulative OR was 1.59 ( ). The very low sampleP ! .0001
sizes for some disease subgoups make it impossible to
draw definitive conclusions for all diseases. Nevertheless,
the absence of any evidence of association of PTPN22
with MS is striking, given that 120 patients with MS
were available for study, and this confirms recent data
(Begovich et al. 2005). Positive associations with T1D,
RA, SLE, Graves disease, and autoimmune Addison dis-
ease have been reported elsewhere (Begovich et al. 2004;
Bottini et al. 2004; Kyogoku et al. 2004; Smyth et al.
2004; Velaga et al. 2004). We also examined PTPN22
associations in individuals with more than one auto-
immune disorder (data not shown). Since most of these
individuals had AITD as one of these diseases (see above),
it is not surprising that the OR for this group (OR 1.73;
95% CI 1.17–2.55) was very similar to that seen for
Hashimoto thyroiditis alone.
The significant association with Hashimoto thyroiditis
is a novel observation. To address any concern about
including multiple affected members from the same fam-
ily in a case-control analysis, we performed an asso-
ciation analysis by restricting the cases with Hashimoto
thyroiditis to one affected sibling per sibship (165 in-
dividuals). A particular random sampling of one affected
sibling per sibship led to a T-allele frequency of 13.9%,
an OR of 1.70, a 95% CI of 1.20–2.42, and a P value
of .003. We repeated this random sampling 100 times;
the averaged T-allele frequency is 13.91%, with an SD
of 0.37%, which is consistent with the result given in
table 5.
Discussion
Autoimmune diseases constitute a diverse set of related
phenotypes that are presumed to have common under-
lying mechanisms and, thus, some degree of shared ge-
netic predisposition (Becker 2001). The diversity of phe-
notypes among autoimmune diseases makes them dif-
ficult to study as a unified group, and their relative rarity
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as individual diseases poses a challenge for accumulating
sufficient sample sizes that contain specific disease sub-
groups or subphenotypes. In general, with the exception
of the HLA region, attempts to identify genes that confer
genetic predisposition across the different autoimmune
diseases have been unsuccessful or, in the case of CTLA4,
have provided only modest and incomplete evidence that
a common allele underlies different forms of autoim-
munity (Ueda et al. 2003). Several recent reports suggest
that another member of the CTLA4 family of T-cell reg-
ulatory receptors, PD-1, may also predispose to several
autoimmune diseases (Prokunina et al. 2002, 2004; Niel-
sen et al. 2003; Lin et al. 2004).
The MADGC collection of families was originally con-
ceived to be a resource for identifying the common ge-
netic elements involved in autoimmunity and was based
on the idea that certain alleles may act to predispose to
multiple autoimmune diseases. We posited that genes act-
ing across autoimmune phenotypes would be enriched in
families in whom multiple different autoimmune phe-
notypes are present. These might be common genes with
low penetrance, and, thus, they would probably also be
found in sporadic disease or in families with only one
autoimmune phenotype. Alternatively, more rare and
highly penetrant genes for autoimmunity may also be
present in the population, and these will likely only be
detected by focusing on larger multiplex families. The
MADGC collection provides a valuable resource for iden-
tifying both types of autoimmunity genes.
In this study, we show that a relatively common variant
of PTPN22, 620W, confers susceptibility for four differ-
ent autoimmune disorders: T1D, RA, SLE, and Hashi-
moto thyroiditis. There have been initial reports of sep-
arate associations of PTPN22 with three of these diseases
(Begovich et al. 2004; Bottini et al. 2004; Kyogoku et al.
2004). This is the first reported association with Hash-
imoto thyroiditis. The OR for Graves disease was 11,
but our sample size was inadequate to definitively address
this question. However, two recent reports have shown
clear evidence of association with Graves disease (Smyth
et al. 2004; Velaga et al. 2004). In contrast, the lack of
association with MS is of interest, since the sample size
of MS cases in this data set ( ) provides a rea-np 120
sonable likelihood of detecting such an association. For
this analysis, a case sample size of 120 has 62% power
to detect an OR of 1.8, under the assumption of a control
risk-allele frequency of 0.085. Furthermore, this lack of
association has recently been confirmed in a larger MS
data set (Begovich et al. 2005).
These results have implications for the diversity of
pathogenic mechanisms that are likely to underlie au-
toimmune diseases. It is clear that PTPN22 is directly
involved in setting thresholds for T-cell receptor (TCR)
signaling and, in this context, is acting, in part, through
binding to intracellular kinases such as Csk (Gregorieff
et al. 1998; Cloutier and Veillette 1999). These interac-
tions control the phosphorylation state of regulatory ty-
rosines on key signaling molecules in the TCR complex,
such as Lck and ZAP70 (Mustelin et al. 2004). PTPN22-
knockout animals display rather subtle changes in a
number of immune parameters (Hasegawa et al. 2004)—
most prominently, in the enhanced T-cell proliferation
in the memory-effector compartment. In the older an-
imals (aged 6 mo), there was an expansion in the number
of T cells and an enlargement of the spleen and the lymph
nodes. This was accompanied by the spontaneous for-
mation of germinal centers and higher levels of several
Ig isotypes. Thus, there was an up-regulation of the hu-
moral immune response in these animals that appeared
to be largely secondary to lowered thresholds for sig-
naling in T cells (Hasegawa et al. 2004).
The existence of humoral abnormalities in the
PTPN22-knockout mice is consistent with the fact that
autoantibody production is a prominent feature of all the
human diseases that are associated with PTPN22. In-
deed, SLE, RA, T1D, and Hashimoto thyroiditis are all
characterized by the frequent development of autoanti-
bodies, often before the onset of clinical disease (Arbuckle
et al. 2003; Strieder et al. 2003; Hoppu et al. 2004;
Nielen et al. 2004). We also have recently shown that
the PTPN22 association is almost exclusively with se-
ropositive RA (Begovich et al. 2004; Lee et al., in press).
In addition, the formation of ectopic germinal centers
can be seen in both RA and AITD (Weyand et al. 2001),
and increased germinal center formation is observed in
autoimmune mouse models for SLE and T1D (Luzina et
al. 2001). In contrast, human MS does not appear to
have a prominent humoral component (Haffler 2004).
These combined observations suggest that the PTPN22
620W risk allele may act primarily as a predisposing
factor for the development of autoantibodies in these
disorders. It will therefore be of great interest to examine
(1) whether the PTPN22 risk allele is also associated with
the presence of autoantibodies in individuals who do not
display a clinical phenotype and (2) whether PTPN22
confers additional risk of the eventual development of
clinical autoimmunity in these individuals. The MADGC
families should be useful for such an investigation, since
we have recruited many unaffected individuals in these
families and plasma is available for additional antibody
testing of all subjects.
The absence of an association with MS appears to
imply that lowered thresholds for TCR signaling may not
have an important role in the predisposition to MS, at
least at stages of T-cell differentiation in which PTPN22
levels are critical for regulation. This is somewhat sur-
prising, given the wealth of data implicating T cells in
the pathogenesis of this disease (Haffler 2004). However,
knowledge is still very incomplete concerning exactly
which T-cell subsets depend on PTPN22 for regulation.
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Overall, phosphatases have a negative regulatory func-
tion in T cells, and there may be other phosphatases,
such as PTP-PEST (another Csk-binding phosphatase),
that might serve a function that is redundant to PTPN22
in certain cell types (Mustelin et al. 2004). It should also
be pointed out that PTPN22 is broadly expressed in he-
matopoietic cells, and, thus, the mechanism for disease
susceptibility may extend beyond T cells (Begovich et al.
2004). Knowledge of the regulatory circuits controlled
by phosphatases in T lymphocytes (or other cell types),
combined with population-genetics data such as we de-
scribe here, may eventually make it possible for research-
ers to identify the critical lymphocyte subsets and path-
ogenic mechanisms that are involved in the different
autoimmune diseases.
The overall goal of the MADGC is to collect family
data that will facilitate the identification of genes that
predispose to multiple different autoimmune diseases.
Data from additional families are currently being col-
lected to increase the statistical power for future studies
of putative disease-susceptibility alleles, as they are dis-
covered. We intend to pursue a more detailed analysis of
intermediate phenotypes in this family collection, includ-
ing a comprehensive analysis of autoantibodies in both
affected and unaffected individuals. Data from these fam-
ilies can also be used to examine other biomarkers that
may be relevant to autoimmunity, including patterns of
gene expression (Baechler et al. 2003). Numerous other
questions need to be addressed, including the significance
of female predominance among the affected individuals
in these families and the possible role of environmental
factors in accounting for familial aggregation. The very
large extended pedigrees in this collection may be useful
in linkage analyses for the identification of rare, high-
penetrance genes. Finally, the data from these families
may prove to be particularly useful for discovering gene-
gene interactions, under the assumption that the final
autoimmune phenotype depends on an interaction of
common autoimmunity genes with more disease-specific
susceptibility alleles segregating in these families. It is
likely that very large sample sizes will be required to
successfully perform such studies, since stochastic and
environmental factors will complicate the elucidation of
these relationships.
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